Placental Organoids Development: Application in the Study of the Human Reproduction Pathophysiology.

Sponsor
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study ID
NCT06893978
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Healthy
  • Preeclampsia
  • Pregnancy Loss
  • Preterm Birth

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Placenta organoids treatment — DRUG
    Placenta organoids in vitro treatment with heparin, aspirin, IVIG, filgrastim and metformin

Study Details

Placental organoids represent an in vitro 3D reconstruction model of the human placenta and of its complex cellular organization to evaluate the pharmacological effect in terms of placentation, gene expression, protein synthesis and placental secretomics.

Key Dates

First listed
Mar 25, 2025
Start date
May 20, 2025
Status verified
Nov 2024
Primary completion
Nov 30, 2027
Completion
Nov 30, 2027

Study Design

Enrollment
20 participants (estimated)

Primary Outcome Measure

Development of placental 3D organoid model [ Time Frame: From the date of caesarean section until the development of placental organoids, assessed up to 36 months. ]

Central Contacts

Related Studies